Europe Needle Free Injection Market is Segmented By Type (Liquid-based, Projectile, Powder-based), By Application (Vaccine Delivery, Insulin Delivery, Pain Management, Others), By End-User (Hospital, Clinics, Home Care settings, Others), and By Country (Germany, U.K., France, Italy, Spain, Rest of Europe) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Europe Needle Free Injection Market Size
The Europe needle free injection market size was valued at US$ 43.77 million in 2022 and is estimated to reach US$ 71.20 million by 2030, exhibiting at CAGR of 6.4% during the forecast period (2023-2030).
Needle free injection technology contains a broad range of drug delivery systems that drive drugs via the skin using forces such as shock waves, Lorentz, and pressure by gas or electrophoresis, which virtually moves the drug via the skin nullifying the use of a hypodermic needle. The devices are available in reusable forms.
Europe Needle-Free Injection Market Scope
|
Metrics |
Details |
|
CAGR |
6.4% |
|
Size Available for Years |
2021-2030 |
|
Forecast Period |
2023-2030 |
|
Data Availability |
Value (US$) |
|
Segments Covered |
Type, Application, End-User, and Region |
|
Countries Covered |
Germany, U.K., France, Italy, Spain, Rest of Europe |
|
Largest Country |
U.K. |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
To Know More Insights - Download Sample
Source: DataM Intelligence Analysis (2022)
Europe Needle Free Injection Market Dynamics
The Europe needle free injection market growth is driven by technological advancements, increasing number of regulatory approvals, a rising prefererence of self-administration of drugs, rising patient awareness, growing chronic diseases, and rising patient healthcare expenditure.
An increasing number of chronic diseases in European countries drives the market growth
The increasing number of chronic diseases such as kidney disease and technological advancements drive the market growth worldwide. According to European Chronic Disease Alliance, cardiovascular disease (CVD) causes 3.9 million deaths annually in Europe and over 1.8 million deaths in the E.U. CVD accounts for 45% of all deaths in Europe and 37% in the E.U. Also, one in eight deaths in the E.U. is due to respiratory diseases and 600,000 people die each year in the EU from respiratory diseases. In addition, 58 million people are living with diabetes, and 36 million more are at risk of developing the condition in Europe. Each year 477, 000 people die of diabetes-related complications, and our health systems spend EUR 143 billion on the direct costs of the disease. About 10% of the population is affected by chronic kidney disease (CKD). About 70 million Europeans have lost some kidney function, and one in 3 Europeans is at an increased risk of developing CKD.
Furthermore, the market players are adopting market strategies such as product launches and collaboration to expand their business. For instance, in May 2022, Gerresheimer AG expanded its portfolio of highly-innovative platform technologies for drug delivery. Gerresheimer, a provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, announced an investment in the U.S.-based Portal Instruments, a next-generation needle-free drug delivery technology developer. Together, the partners aim to transform injectable medicines' administration and improve the patient's experience, especially for those with chronic diseases.
Also, in December 2021, The NIHR Southampton Clinical Research Facility (CRF) launched a trial for a pioneering vaccine technology that could be used as a booster targeting COVID-19 virus variants and relatives that threaten future coronavirus pandemics. This first next-generation coronavirus vaccine uses the University of Cambridge DIOSvax technology. It will be given without a needle, using an air jet to push it under the skin. This provides a possible future alternative to people who fear needle-based jabs.
The drawbacks associated with needle free injection will hamper the growth of the market
However, the major drawback associated with this technology is post-administration wetness of the skin which may, if not taken care of, harbor dust and other untoward impurities. Also, with higher requirements for training and maintenance, no one size fits all NFID limits the market growth. In addition, the FDA is aware that needle-free devices and lip and facial fillers for use with these devices are sold online directly to the public, and their use is promoted on social media to increase lip volume, improve the appearance of wrinkles, change the shape of the nose, and other similar procedures.
COVID-19 Impact Analysis
The COVID-19 pandemic has positive effect on needle free injection market. Needle-free injections are an alternative drug delivery system that uses high pressure to deliver medication through the skin without a traditional needle. During the COVID-19 pandemic, there has been increased interest in needle-free injections to lessen the risk of virus transmission through the shared use of needles.
Needle phobia is a well-known problem, with estimations suggesting that the adult population strongly fears injections. One study conducted in the UK found that approximately 10% of cases of COVID-19 vaccine hesitancy could be linked to fear of injection. Providing an alternative means of delivery could, therefore, increase the effectiveness of vaccination programs.
In Europe, many countries have embraced needle-free injections as part of their response to the pandemic. For example, the UK National Health Service (NHS) has recommended using needle-free injections for certain vaccinations to reduce the risk of COVID-19 transmission. Additionally, many countries have implemented national campaigns to promote needle-free injections to increase vaccine uptake and protect public health.
Europe Needle Free Injection Market Segment Analysis
The vaccine delivery segment is expected to grow at the fastest CAGR during the forecast period (2021-2030)
The vaccine delivery segment accounts for the highest market share. As per the article published in nanoday in 2023, better immunogenicity is offered by a needle-free mRNA vaccine delivery technology than by a needle injection. Using a high-pressure source, needle-free injection (NFI) technology creates fast-moving liquid jets that can pierce the epidermis and dermis to deliver medication to the subcutaneous or intramuscular layer. Various vaccines, including the inactivated polio vaccine (IPV), influenza vaccine, hepatitis B vaccine, human papillomavirus vaccine (HPV), and diphtheria pertussis tetanus (DPT) vaccine, have been administered using NFI-delivery via intradermal and intramuscular injections.
In October 2021, Enesi Pharma, an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax technologies, agreed with the US National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to test a novel ImplaVax enabled pandemic flu vaccine. ImplaVax-enabled vaccination products leverage Enesi’s innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies and are applicable across all vaccine formats.
Source: DataM Intelligence Analysis (2022)
Europe Needle Free Injection Market Geographical Share
The U.K. holds the largest market share of the Europe needle free injection market
The U.K. dominates the market for needle free injections and is expected to show a similar trend over the forecast period. The market is driven by technological advancements, increased awareness and concern for safety, growing prevalence of chronic diseases, government initiatives, and rising demand for home healthcare in the U.K.
The need for safer, less invasive, and more convenient drug delivery methods is a key driver for the growth of the needle-free injection market in the U.K. Using needle-free injections can help to reduce the risk of needle-stick injuries, infections, and other safety concerns associated with traditional needle injections. This is particularly important in settings where frequent injections are required, such as in the case of patients with chronic diseases.
In addition, the University of Southampton is employing DIOSvax technology to create a novel needle-free vaccination currently undergoing testing in the UK. In contrast to Pfizer and Moderna vaccines, the vaccination employs a jet of air to push through the skin instead of a needle.
Source: DataM Intelligence Analysis (2022)
Europe Needle Free Injection Market Companies and Competitive Landscape
The needle-free injection market has a moderately competitive presence of local and domestic companies. Some of the key players contributing to the growth of the market are Antares Pharma, PharmaJet, Fierce Pharma, Medical International Technology, INJEX Pharma, European Pharma Group, Crossject, Portal Instruments, Valeritas Inc., and Bioject Medical Technologies Inc., among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations. For instance, in May 2022, Halozyme acquired Antares Pharma, Inc., developing a leading drug delivery business with broadly licensable opportunities across ENHANZE and Antares’ auto-injector technologies.
PharmaJet
Overview:
PharmaJet’s Needle-free Systems offer improved vaccine effectiveness, a selected patient and caregiver experience, and a proven path to commercialization. They are also secure, quick, and easy to use. The company provides two products, TROPIS and STRATIS.
Product Portfolio:
Stratis IM/SC: The Stratis Needle-free Injection System provides accurate and consistent 0.5 ml intramuscular and subcutaneous injections to help patients to achieve better results with their pharma products.
The Europe needle-free injection market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.
